Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Pre-B acute lymphoblastic leukemia expresses cell surface nucleolin as a 9-O-acetylated sialoglycoprotein.

Joo EJ, Wasik BR, Parrish C, Paz H, Mϋhlenhoff M, Abdel-Azim H, Groffen J, Heisterkamp N.

Sci Rep. 2018 Nov 21;8(1):17174. doi: 10.1038/s41598-018-33873-2.

2.

Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.

Paz H, Joo EJ, Chou CH, Fei F, Mayo KH, Abdel-Azim H, Ghazarian H, Groffen J, Heisterkamp N.

J Exp Clin Cancer Res. 2018 Mar 27;37(1):67. doi: 10.1186/s13046-018-0721-7.

3.

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL.

Adam E, Kim HN, Gang EJ, Schnair C, Lee S, Lee S, Khazal S, Kosoyan O, Konopleva M, Parekh C, Bhojwani D, Wayne AS, Abdel-Azim H, Heisterkamp N, Kim YM.

Cancers (Basel). 2017 Sep 10;9(9). pii: E121. doi: 10.3390/cancers9090121.

4.

Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response.

Sheng X, Tucci J, Parmentier JH, Ji L, Behan JW, Heisterkamp N, Mittelman SD.

Oncotarget. 2016 Nov 8;7(45):73147-73159. doi: 10.18632/oncotarget.12246.

5.

How to avoid being eaten: a lymphoma's defense.

Heisterkamp N.

Blood. 2016 Apr 14;127(15):1842-3. doi: 10.1182/blood-2016-03-701680.

6.

Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.

George AA, Paz H, Fei F, Kirzner J, Kim YM, Heisterkamp N, Abdel-Azim H.

PLoS One. 2015 Sep 11;10(9):e0137917. doi: 10.1371/journal.pone.0137917. eCollection 2015.

7.

Potential of autologous NK cell therapy to eradicate leukemia: "Education is [not] the best provision for old age" -Aristotle.

Abdel-Azim H, Heisterkamp N.

Oncoimmunology. 2015 Mar 6;4(2):e984549. eCollection 2015 Feb. Review.

8.

B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3.

Fei F, Joo EJ, Tarighat SS, Schiffer I, Paz H, Fabbri M, Abdel-Azim H, Groffen J, Heisterkamp N.

Oncotarget. 2015 May 10;6(13):11378-94.

9.

Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells.

Fei F, Lim M, George AA, Kirzner J, Lee D, Seeger R, Groffen J, Abdel-Azim H, Heisterkamp N.

Leukemia. 2015 Apr;29(4):788-97. doi: 10.1038/leu.2014.246. Epub 2014 Aug 19.

10.

Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R.

Parameswaran R, Lim M, Fei F, Abdel-Azim H, Arutyunyan A, Schiffer I, McLaughlin ME, Gram H, Huet H, Groffen J, Heisterkamp N.

Mol Cancer Ther. 2014 Jun;13(6):1567-77. doi: 10.1158/1535-7163.MCT-13-1023. Epub 2014 May 13.

11.

Abr, a negative regulator of Rac, attenuates cockroach allergen-induced asthma in a mouse model.

Gong D, Fei F, Lim M, Yu M, Groffen J, Heisterkamp N.

J Immunol. 2013 Nov 1;191(9):4514-20. doi: 10.4049/jimmunol.1202603. Epub 2013 Sep 20.

12.

Galectin-3 in pre-B acute lymphoblastic leukemia.

Fei F, Abdel-Azim H, Lim M, Arutyunyan A, von Itzstein M, Groffen J, Heisterkamp N.

Leukemia. 2013 Dec;27(12):2385-8. doi: 10.1038/leu.2013.175. Epub 2013 Jun 13. No abstract available.

13.

O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia.

Parameswaran R, Lim M, Arutyunyan A, Abdel-Azim H, Hurtz C, Lau K, Müschen M, Yu RK, von Itzstein M, Heisterkamp N, Groffen J.

J Exp Med. 2013 Apr 8;210(4):805-19. doi: 10.1084/jem.20121482. Epub 2013 Mar 11.

14.

Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy.

Pramanik R, Sheng X, Ichihara B, Heisterkamp N, Mittelman SD.

Leuk Res. 2013 May;37(5):503-9. doi: 10.1016/j.leukres.2012.12.013. Epub 2013 Jan 17.

15.

Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.

Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Shojaee S, Klemm L, Parameswaran R, Loh M, Kang ES, Koo HH, Hofmann WK, Andrade J, Crooks GM, Willman CL, Müschen M, Papayannopoulou T, Heisterkamp N, Bönig H, Kim YM.

Blood. 2013 Mar 7;121(10):1814-8. doi: 10.1182/blood-2012-01-406272. Epub 2013 Jan 14.

16.

Lack of bcr and abr promotes hypoxia-induced pulmonary hypertension in mice.

Yu M, Gong D, Lim M, Arutyunyan A, Groffen J, Heisterkamp N.

PLoS One. 2012;7(11):e49756. doi: 10.1371/journal.pone.0049756. Epub 2012 Nov 12.

17.

Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia.

Feldhahn N, Arutyunyan A, Stoddart S, Zhang B, Schmidhuber S, Yi SJ, Kim YM, Groffen J, Heisterkamp N.

Oncoimmunology. 2012 Aug 1;1(5):618-629.

18.

Expression of cassini, a murine gamma-satellite sequence conserved in evolution, is regulated in normal and malignant hematopoietic cells.

Arutyunyan A, Stoddart S, Yi SJ, Fei F, Lim M, Groffen P, Feldhahn N, Groffen J, Heisterkamp N.

BMC Genomics. 2012 Aug 23;13:418. doi: 10.1186/1471-2164-13-418.

19.

Regulation of dendritic arborization by BCR Rac1 GTPase-activating protein, a substrate of PTPRT.

Park AR, Oh D, Lim SH, Choi J, Moon J, Yu DY, Park SG, Heisterkamp N, Kim E, Myung PK, Lee JR.

J Cell Sci. 2012 Oct 1;125(Pt 19):4518-31. doi: 10.1242/jcs.105502. Epub 2012 Jul 5.

20.

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).

Fei F, Lim M, Schmidhuber S, Moll J, Groffen J, Heisterkamp N.

Mol Cancer. 2012 Jun 21;11:42. doi: 10.1186/1476-4598-11-42.

21.

TGFβ signaling plays a critical role in promoting alternative macrophage activation.

Gong D, Shi W, Yi SJ, Chen H, Groffen J, Heisterkamp N.

BMC Immunol. 2012 Jun 15;13:31. doi: 10.1186/1471-2172-13-31.

22.

Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.

Parameswaran R, Yu M, Lyu MA, Lim M, Rosenblum MG, Groffen J, Heisterkamp N.

Leukemia. 2012 Aug;26(8):1786-96. doi: 10.1038/leu.2012.54. Epub 2012 Feb 29.

23.

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.

Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM.

Blood. 2011 Aug 25;118(8):2191-9. doi: 10.1182/blood-2011-04-351239. Epub 2011 Jun 28.

24.

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.

Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Müschen M.

Nature. 2011 May 19;473(7347):384-8. doi: 10.1038/nature09883.

25.

Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome.

Chandra HS, Heisterkamp NC, Hungerford A, Morrissette JJ, Nowell PC, Rowley JD, Testa JR.

Cancer Genet. 2011 Apr;204(4):171-9. doi: 10.1016/j.cancergen.2011.03.002.

26.

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.

Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N.

Leukemia. 2011 Aug;25(8):1314-23. doi: 10.1038/leu.2011.76. Epub 2011 Apr 12.

27.

AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo.

Yu M, Gang EJ, Parameswaran R, Stoddart S, Fei F, Schmidhuber S, Park E, Hsieh YT, Yang AS, Groffen J, Heisterkamp N, Kim YM.

Blood Cancer J. 2011 Apr;1(4):e14. doi: 10.1038/bcj.2011.13. Epub 2011 Apr 1. No abstract available.

28.

Bcr is a substrate for Transglutaminase 2 cross-linking activity.

Yi SJ, Groffen J, Heisterkamp N.

BMC Biochem. 2011 Feb 10;12:8. doi: 10.1186/1471-2091-12-8.

29.

The Fer tyrosine kinase regulates interactions of Rho GDP-Dissociation Inhibitor α with the small GTPase Rac.

Fei F, Kweon SM, Haataja L, De Sepulveda P, Groffen J, Heisterkamp N.

BMC Biochem. 2010 Dec 1;11:48. doi: 10.1186/1471-2091-11-48.

30.

Regulation of synaptic Rac1 activity, long-term potentiation maintenance, and learning and memory by BCR and ABR Rac GTPase-activating proteins.

Oh D, Han S, Seo J, Lee JR, Choi J, Groffen J, Kim K, Cho YS, Choi HS, Shin H, Woo J, Won H, Park SK, Kim SY, Jo J, Whitcomb DJ, Cho K, Kim H, Bae YC, Heisterkamp N, Choi SY, Kim E.

J Neurosci. 2010 Oct 20;30(42):14134-44. doi: 10.1523/JNEUROSCI.1711-10.2010.

31.

Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models.

Yun JP, Behan JW, Heisterkamp N, Butturini A, Klemm L, Ji L, Groffen J, Müschen M, Mittelman SD.

Cancer Prev Res (Phila). 2010 Oct;3(10):1259-64. doi: 10.1158/1940-6207.CAPR-10-0087. Epub 2010 Sep 7.

32.

Cell type-specific expression of adenomatous polyposis coli in lung development, injury, and repair.

Li A, Xing Y, Chan B, Heisterkamp N, Groffen J, Borok Z, Minoo P, Li C.

Dev Dyn. 2010 Aug;239(8):2288-97. doi: 10.1002/dvdy.22364.

33.

A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias.

Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N.

Cancer Res. 2010 Jun 1;70(11):4346-56. doi: 10.1158/0008-5472.CAN-10-0300. Epub 2010 May 11.

34.

Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.

Fei F, Stoddart S, Groffen J, Heisterkamp N.

Mol Cancer Ther. 2010 May;9(5):1318-27. doi: 10.1158/1535-7163.MCT-10-0069. Epub 2010 Apr 13.

35.

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.

Fei F, Stoddart S, Müschen M, Kim YM, Groffen J, Heisterkamp N.

Leukemia. 2010 Apr;24(4):813-20. doi: 10.1038/leu.2009.302. Epub 2010 Jan 28.

36.

Transglutaminase 2 regulates the GTPase-activating activity of Bcr.

Yi SJ, Groffen J, Heisterkamp N.

J Biol Chem. 2009 Dec 18;284(51):35645-51. doi: 10.1074/jbc.M109.062240.

37.

Adipocytes impair leukemia treatment in mice.

Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS, Avramis VI, Louie SG, Butturini A, Heisterkamp N, Mittelman SD.

Cancer Res. 2009 Oct 1;69(19):7867-74. doi: 10.1158/0008-5472.CAN-09-0800. Epub 2009 Sep 22.

38.

The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.

Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M.

Cancer Cell. 2009 Sep 8;16(3):232-45. doi: 10.1016/j.ccr.2009.07.030.

39.

Bcr and Abr cooperate in negatively regulating acute inflammatory responses.

Cunnick JM, Schmidhuber S, Chen G, Yu M, Yi SJ, Cho YJ, Kaartinen V, Minoo P, Warburton D, Groffen J, Heisterkamp N.

Mol Cell Biol. 2009 Nov;29(21):5742-50. doi: 10.1128/MCB.00357-09. Epub 2009 Aug 24.

40.

Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.

Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, Storlazzi CT, Jäck HM, Groffen J, Martinelli G, Heisterkamp N, Jumaa H, Müschen M.

J Exp Med. 2009 Aug 3;206(8):1739-53. doi: 10.1084/jem.20090004. Epub 2009 Jul 20.

41.

Bcr/Abl P190 interaction with Spa-1, a GTPase activating protein for the small GTPase Rap1.

Yi SJ, Lee HT, Groffen J, Heisterkamp N.

Int J Mol Med. 2008 Oct;22(4):453-8.

PMID:
18813851
42.

The human gamma-glutamyltransferase gene family.

Heisterkamp N, Groffen J, Warburton D, Sneddon TP.

Hum Genet. 2008 May;123(4):321-32. doi: 10.1007/s00439-008-0487-7. Epub 2008 Mar 21.

PMID:
18357469
43.

Activity of the Bcr GTPase-activating domain is regulated through direct protein/protein interaction with the Rho guanine nucleotide dissociation inhibitor.

Kweon SM, Cho YJ, Minoo P, Groffen J, Heisterkamp N.

J Biol Chem. 2008 Feb 8;283(6):3023-30. Epub 2007 Dec 10.

44.

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.

Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, Groffen J, Heisterkamp N.

Mol Cancer. 2007 Oct 25;6:67.

45.

Sprouty2 downregulation plays a pivotal role in mediating crosstalk between TGF-beta1 signaling and EGF as well as FGF receptor tyrosine kinase-ERK pathways in mesenchymal cells.

Ding W, Shi W, Bellusci S, Groffen J, Heisterkamp N, Minoo P, Warburton D.

J Cell Physiol. 2007 Sep;212(3):796-806.

PMID:
17516543
46.

Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells.

Zhang B, Groffen J, Heisterkamp N.

Leukemia. 2007 Jun;21(6):1189-97. Epub 2007 Mar 29.

PMID:
17392819
47.

TNF-alpha represses transcription of human Bone Morphogenetic Protein-4 in lung epithelial cells.

Zhu NL, Li C, Huang HH, Sebald M, Londhe VA, Heisterkamp N, Warburton D, Bellusci S, Minoo P.

Gene. 2007 May 15;393(1-2):70-80. Epub 2007 Feb 3.

48.

Abr and Bcr, two homologous Rac GTPase-activating proteins, control multiple cellular functions of murine macrophages.

Cho YJ, Cunnick JM, Yi SJ, Kaartinen V, Groffen J, Heisterkamp N.

Mol Cell Biol. 2007 Feb;27(3):899-911. Epub 2006 Nov 20.

49.

Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2.

Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J, Kazimierczuk Z, Pinna LA, Heisterkamp N.

Leukemia. 2007 Jan;21(1):178-80. Epub 2006 Nov 2. No abstract available.

PMID:
17082777
50.

Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.

Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J.

Cancer Res. 2006 May 15;66(10):5387-93.

Supplemental Content

Loading ...
Support Center